Comparing of Agios Pharmaceuticals Inc. (AGIO) and Taiwan Liposome Company Ltd. (NASDAQ:TLC)

Both Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Taiwan Liposome Company Ltd. (NASDAQ:TLC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 115.85M 24.35 348.28M -5.99 0.00
Taiwan Liposome Company Ltd. N/A 0.00 N/A -0.51 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Agios Pharmaceuticals Inc. and Taiwan Liposome Company Ltd.

Profitability

Table 2 shows Agios Pharmaceuticals Inc. and Taiwan Liposome Company Ltd.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. -300.63% -48.2% -38.6%
Taiwan Liposome Company Ltd. 0.00% 0% 0%

Analyst Recommendations

Recommendations and Ratings for Agios Pharmaceuticals Inc. and Taiwan Liposome Company Ltd. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 2 3.00
Taiwan Liposome Company Ltd. 0 0 0 0.00

Agios Pharmaceuticals Inc.’s upside potential is 56.09% at a $75 average target price.

Institutional & Insider Ownership

Roughly 0% of Agios Pharmaceuticals Inc. shares are held by institutional investors while 2.46% of Taiwan Liposome Company Ltd. are owned by institutional investors. Insiders held roughly 0.3% of Agios Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. -8.33% -20.89% -12.36% -31.47% -45.54% 2.69%
Taiwan Liposome Company Ltd. -8.45% -8.92% -14.88% 0% 0% -3.45%

For the past year Agios Pharmaceuticals Inc. has 2.69% stronger performance while Taiwan Liposome Company Ltd. has -3.45% weaker performance.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.